VUNO, a medical AI company, said Wednesday it has signed a business agreement with medical content platform company Weknew to develop a patient-centered healthcare industry using artificial intelligence.
Under the agreement, the two companies will jointly develop various medical content targeted at people with chronic diseases and provide it to VUNO's chronic disease management mobile app, HativCare.
HativCare is a mobile app under Hativ, a chronic disease management brand launched by VUNO in January. In addition to measuring electrocardiograms, the app records and manages biometric data, such as blood pressure, blood sugar, and weight. Its community feature allows users to share their concerns about the disease, lifestyle improvements, and management know-how.
"This collaboration enables us to provide users with content that helps them manage their health in their daily lives,” VUNO CEO Lee Ye-ha said. “We will continue to add more features to the HativCare app over time to make it the centerpiece of a future healthcare platform that connects individuals and hospitals."
Related articles
- VUNO patents AI-based medical image analysis tech in US
- VUNO, Severance sign MOU to develop AI-based rare disease detection tech
- VUNO’s device warns against cardiac arrest in pediatric inpatients: study
- Korean AI medical imaging companies show impressive surge in share prices
- SPASS gets FDA clearance for AI-based sepsis diagnosis solution
- VUNO founder launches AI eye disease management startup
- FDA OKs VUNO's brain imaging analysis device